HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Section

Deals

M&A, licensing, and major transactions shaping the industry

Zydus to acquire Assertio in $166m deal
DealsPharmaceutical Technology ↗
Zydus Lifesciences is set to acquire all outstanding Assertio common shares in a $166.4m deal, via its subsidi…
May 14, 2026
Novo salvages happy ending for scrapped Parkinson’s cell therapy via deal with AI biotech
DealsFierceBiotech ↗
Novo Nordisk has found the latest buyer for one of its orphaned cell therapies.…
May 14, 2026
Bayer to make 'careful but aggressive' return to pharma M&A, CEO says
DealsEndpoints News ↗
Bayer is back on the market for drug acquisitions after a half-decade on the sidelines, according to CEO Bill …
May 12, 2026
BMS Bets on China’s Speed in $15B Hengrui R&D Pact
DealsBriefing
Bristol Myers Squibb will pay $600M upfront in a $15.2B collaboration with Hengrui, aiming to leverage China’s…
May 12, 2026
GSK cuts deal with Sino to broaden reach of hepatitis B drug
DealsBioPharma Dive ↗
The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and c…
May 11, 2026
Blackstone invests $250M in Anagram to reduce burden of cystic fibrosis complication
DealsFierceBiotech ↗
For people living with exocrine pancreatic insufficiency due to cystic fibrosis, the only treatment option is …
May 10, 2026
← Newer Page 3 Older →
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.